Posted by Michael Wonder on 12 Sep 2019
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
12 September 2019 - GlaxoSmithKline today announced that the US FDA has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma.
Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US.
The FDA approval is supported by an open-label study, conducted in children aged six to 11 years and suffering from severe eosinophilic asthma, that investigated Nucala’s pharmacokinetics, pharmacodynamics and long-term safety.
